盐酸安罗替尼治疗化疗进展后晚期肺鳞癌的临床观察  

Anlotinib hydrochloride for advanced squamous cell lung carcinoma following chemotherapy:a clinical observation

作　　者：莫奉山[1] 刘良波 曾湖[1] 蔡茂德[1] MO Feng-shan;LIU Liang-bo;ZENG Hu;CAI Mao-de(Second Ward,Department of Oncology,Gaozhou People's Hospital,Maoming 525200,China)

机构地区：[1]广东省高州市人民医院肿瘤内科二区,茂名525200

出　　处：《中国肿瘤临床与康复》2021年第10期1181-1184,共4页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨盐酸安罗替尼治疗化疗进展后的晚期肺鳞癌的临床观察。方法选取2019年5月至2021年3月间高州市人民医院收治的84例晚期肺鳞癌患者,按照治疗方式不同分为研究组和对照组,每组42例。研究组患者采用盐酸安罗替尼治疗,对照组患者采用传统吉西他滨联合铂类双药化疗方案治疗,比较两组患者的临床有效率、生存率、肿瘤标记物和生活质量。结果研究组患者治疗总有效率为83.3%,高于对照组的71.4%,差异有统计学意义(P<0.05)。研究组患者3个月和6个月生存率均高于对照组,差异均有统计学意义(均P<0.05)。治疗前,两组患者肿瘤标记物比较,差异无统计学意义(P>0.05)。治疗后,研究组患者肿瘤标记物水平均低于对照组,差异均有统计学意义(均P<0.05)。治疗前,两组患者生命质量评分比较,差异无统计学意义(P>0.05)。治疗后,研究组患者症状领域和癌症症状分数较对照组低,功能领域和总健康状况得分较对照组高,差异均有统计学意义(均P<0.05)。结论化疗进展后的晚期肺鳞癌患者采用盐酸安罗替尼治疗,可改善患者的生活质量,降低肿瘤标记物含量,提升治疗效果,延长生存时间,值得应用。Objective To study the clinical significance of anlotinib hydrochloride for advanced squamous cell lung carcinoma following the chemotherapy.Methods Eighty-four patients with advanced squamous cell lung carcinoma were selected from May 2019 to March 2020.According to different thera-pies,they were divided into an experimental group and control group with 42 patients in each group.The experimental group received anlotinib hydrochloride and the control group received chemotherapy with gem-citabine and carboplatin.Treatment efficacy,survival rates,tumor biomarkers and quality of life were com-pared.Results The overall efficacy rate was 83.3%in the experimental group which was higher than 71.4%of the control group(P<0.05).the The 3-and 6-month survival rate was higher in the experimen-tal group than in the control group(all P<0.05).Before the therapy,there was no significant difference in tumor biomarkers between the groups(P>0.05).After the therapy,levels of tumor biomarkers were lower in the experimental group than in the control group(all P<0.05).There was no significant difference in quality of life scores between the two groups(P>0.05).After therapy,quality of life scores in the aspect of symptoms were lower in the experimental group than in the control group and function scores and overall score of quality of life were higher in the experimental group than in the control group(all P<0.05).Con-clusion Anlotinib hydrochloride can improve quality of life,treatment effects and survival time in patients with advanced squamous cell lung carcinoma following the chemotherapy.It deserves promotion in clinical practice.

关 键 词：盐酸安罗替尼 化疗进展 晚期 肺鳞癌 

分 类 号：R734.2[医药卫生—肿瘤]